Stada Sales Increase By 18% In 2020 To Break Through €3bn Barrier
In-Licensing Deals And Acquisitions Help Push Up Group Turnover
Executive Summary
Stada enjoyed double-digit growth for revenues and profitability when adjusted for currency and one-time costs last year, as the privately-owned German firm championed its supply chain investments amid the coronavirus pandemic.
You may also be interested in...
Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings
Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.
Stada Launches Medical Cannabis Portfolio
Stada has announced the launch of its medical cannabis portfolio under the brand CannabiStada in Germany. The company will be rolling out both flowers and whole extracts, primarily geared towards chronic pain patients for whom established medications, such as opioids, do not work.
Who’s Hired? Stada Names New Specialty Head
Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.